{"prompt": "['Novartis', 'Confidential', 'Page 40', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '10 AM 1 hour and other tests must be performed as close as possible to those spirometry', 'times. During the treatment period, two pre-dose spirometry assessments must be', 'performed as follows:', 'First pre-dose spirometry assessment: approximately 45 minutes prior to the dosing', 'of study drug at the clinic visit.', 'Second pre-dose spirometry assessment: approximately 15 minutes prior to the', 'dosing of study drug at the clinic visit.', '8. Reversibility at certain visits (spirometry after administration of SABA) may be', 'performed after 10 AM 1 hour.', '9. In-clinic witnessed dosing of study drug.']['Novartis', 'Confidential', 'Page 41', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Table 6-1', 'Assessment schedule', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'Informed consent and assent (if', 'X', 'ICF must be obtained within 14 days of Visit 1', 'applicable)', 'or at Visit 1.', 'Ask question on withholding of', 'If the patient has not withheld medications as', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'medication before clinic visits', 'specified in the protocol before a particular', 'visit, the visit must be rescheduled.', 'Demographics', 'X', 'Medical history', 'X', 'Medical History - Protocol', 'X', 'solicited events for asthma', 'Asthma exacerbation history', 'X', 'Smoking history', 'X', 'Prior/concomitant medication', 'X', '(asthma and non-asthma', 'X', 'X', 'X', 'medications) review', 'Inclusion/exclusion criteria', 'X', 'Review and record surgeries', 'X', 'X', 'X', 'and procedures', 'Physical examination', 'S', 'S', 'S', 'Abbreviated physical', 'S', 'S', 'S', 'S', 'examination', 'Heart and lungs only.', 'ACQ-5 in clinic', 'X', 'AQLQ+12 in clinic', 'X', 'X']['Novartis', 'Confidential', 'Page 42', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'Train patient and assess', \"patient's ability to use\", 'S', 'eDiary/ePEF and dispense', 'eDiary/ePEF', 'Review eDiary /ePEF', 'S', 'St', 't eDiary/ePEF compliance must be assessed', 'compliance', 'prior to randomizing the patient.', 'Review eDiary/ePEF entries', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'Height', 'X', 'Weight', 'X', 'X', 'Vital signs', 'X', 'X', 'Systolic/diastolic blood pressure, radial pulse', '(sitting), and body temperature.', 'Electrocardiogram', 'X', 'Electrocardiogram (Pre-dose)', 'X', 'Pregnancy testing will begin at the visit a', 'Pregnancy test-serum', 'patient is first identified as being of child', '(women of child bearing', 'X', 'bearing potential.', 'potential)', 'If positive, the patient must not be', 'randomized.', 'Pregnancy testing will begin at the visit a', 'patient is first identified as being of child', 'Pregnancy test-urine dipstick', 'X', 'X', 'X', 'X', 'X', 'bearing potential.', 'test in clinic (women of child', 'X', 'bearing potential)', 'A positive urine pregnancy test requires', 'immediate interruption of study drug until', 'serum \u00df-hCG is performed and found to be']\n\n###\n\n", "completion": "END"}